Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Baxter
Mallinckrodt
Harvard Business School
AstraZeneca
Colorcon

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,645,449

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,645,449
Title:Sensitizing cells for apoptosis by selectively blocking cytokines
Abstract: The invention refers to the use of a cytokine antagonist which modulates the expression and/or the function of a cytokine, particularly a Th2 helper cell cytokine, in a cell and causes the down-regulation of anti-apoptotic proteins in said cell through the cytokine modulation for sensitizing cells for apoptosis. In particular, the cells that can be treated with the cytokine antagonists are drug-resistant cancer cells which fail to undergo apoptosis.
Inventor(s): Stassi; Giorgio, N/A (IT-90127 Palermo, IT), Todaro; Matilde, N/A (IT-90127 Palermo, IT)
Assignee:
Application Number:10/544,794
Patent Claims:1. A method for the down-regulation of an anti-apoptotic protein in a non-lymphoid or non-myeloid tumor of a subject, the method comprising the steps of: (a) selecting a subject having a non-lymphoid or non-myeloid tumor producing a higher level of a cytokine as compared with normal tissue, wherein the cytokine is selected from the group consisting of interleukin (IL)4, IL-5, IL-10, IL-13, and combinations thereof and having a higher level of an anti-apoptotic protein than a comparable control sample; (b) contacting the non-lymphoid or non-lymphoid tumor with a cytokine antagonist; wherein the anti-apoptotic protein in the non-lymphoid or non-myeloid tumor is down-regulated; and wherein cells of the non-lymphoid or non-myeloid tumor are sensitized for cell death; and (c) administering to the subject an active compound or radiotherapy.

2. The method according to claim 1, wherein the anti-apoptotic protein is selected from the group consisting of Bcl-2, Bcl-x.sub.L, cFLIP, Mcl-1, A1, BOO, NR-13, sentrin, TOSO CPAN, PED, DFF45, NAIP, XIAP, cLAP-1, cLAP-2, ML-IAP, KIAP, BIRC5, TIAP, Apollon, fortilin, and combinations thereof.

3. The method according to claim 1, wherein the cytokine antagonist is selected from the group consisting of a transcriptional regulator of the cytokine/cytokine receptor gene, an antisense nucleic acid molecule that is complementary to a region of the cytokine/cytokine receptor gene, a dsRNA molecule that is complementary to the cytokine/cytokine receptor mRNA, a ribozyme that cleaves the cytokine/cytokine receptor mRNA, a translational regulator of the cytokine/cytokine receptor mRNA, an aptamer which binds to the cytokine and/or cytokine receptor and prevents or disrupts the interaction between the cytokine and its receptor, an antibody that binds to the cytokine/cytokine receptor, a receptor, a fragment or derivative thereof of the cytokine, CD124, CD132, IL-13R.alpha.-2, IL-10R.alpha., a cytokine trap, and a cytokine mutein.

4. The method according to claim 3, wherein the cytokine antagonist is an antibody that binds to the cytokine/cytokine receptor.

5. The method according to claim 4, wherein the antibody or fragment thereof is an antibody or fragment thereof that binds to IL-4, IL-10, or IL-13, and combinations thereof.

6. The method according to claim 1, wherein the cytokine antagonist is delivered to the proximity of or into, the non-lymphoid or non-myeloid cancer cell.

7. The method according to claim 6, wherein the cytokine antagonist is delivered via a retroviral vector.

8. The method according to claim 1, wherein the active compound is selected from the group consisting of antimetabolite, a DNA-fragmenting agent, a DNA-crosslinking agent, an intercalating agent, a protein synthesis inhibitor, a topoisomerase I poison, a topoisomerase II poison, a microtubule-directed agent, a kinase inhibitor, an investigational agent, a farnesyl transferase inhibitor, a polyphenol, a hormone, a hormone antagonist, a plant-derived cytostatic, an alkaloid, a podophyllotoxin, an alkylant, a cytotoxic antibiotic, a folic acid analog, a purine analog, a pyrimidine analog, a platinum compound, a monoclonal antibody, an antineoplastic agent, an antineoplastic compound derived from an organ, an antineoplastic compound derived from enzyme, an endocrine effecting an antineoplastic compound belonging to hormones, estrogens, gestagens, hypothalamus hormones, an endocrine effecting an antineoplastic compound belonging to hormone antagonists, antiestrogens, antiandrogens, and an endocrine effecting an antineoplastic compound belonging to enzyme inhibitors.

9. The method according to claim 8, wherein the active compound is selected from the group consisting of cytarabine, fludarabine, 5-fluoro-2'-deoxyuiridine, gemcitabine, hydroxyurea, methotrexate, bleomycin, chlorambucil, cisplatin or cisplatinum, cyclophosphamide, nitrogen mustard, adriamycin, mitoxantrone, L-asparaginase, cycloheximide, puromnycin, diphtheria toxin, camptothecin, topotecan, etoposide, teniposide, colcemid, colchicines, paclitaxel, vinblastine, vincristine, flavopiridol, staurosporin, ST1571 (CPG 57148B), UCN-01 (7-hydroxystaurasporine), PS-341, phenylbutyrate, ET-18-OCH.sub.3, L-739749, L-744832, quercetin, resveratrol, piceatannol, epigallocatechine gallate, theaflavins, flavanols, procyanidins, betulinic acid, glucocorticoids, fenretinide, tamoxifen, finasteride, LHRH antagonists, vindesine, vinorelbin, nimustrine, carmustrine, lomustine, estramustrine, melphalam, ifosfamide, trofosfamide, bendamustine, dacarbazine, busulfane, procarbazine, treosulfene, tremozolamide, thiotepa, aclarubicine, daunorubicine, epirubicine, idarubicine, mitomycine, dactinomycine, methotrexate, cladribin, mercaptopurin, tioguanine, cytarabine, fluorouracil, docetaxel, ghioplatin, carboplatin, oxaliplatin, amsacrine, irinotecane, interferon-.alpha., tretinoine, hydroxycarbamide, miltefosine, pentostatine, aldesleukine, trastuzumab, rituximab, pegaspargase, polyestradiol, fosfestriol, ethinylestradiol, medroxyprogesterone, gestonoroncaproat, megestrol, norethisterone, lynestrenol, triptoreline, leuproreline, busereline, gosereline, testolactone, testosterone, toremifen, flutamide, bicalutamide, cyproterane, anastrol, exemestane, letrozol, formestane, and aminoglutethimide.

10. The method of claim 8, wherein the active compound is co-administered with: (i) a protective selected from the group consisting of calciumfolinat, amifostin, lenograstin molgromostin, filgrastin, and mesna; (ii) an additive selected from the group consisting of retinolpalmitate, thymus D9, and amilomer; or (iii) a combination of (i) and (ii).

11. The method according to claim 1, wherein the active compound is a death receptor agonist.

12. The method according to claim 11, wherein the death receptor agonist is a death receptor ligand selected from the group consisting of TNF-.alpha., TNF-.beta., LT-.beta., TRAIL, CD95 ligand, TRAMP ligand, DR6 ligand, and fragments and derivatives thereof.

13. The method according to claim 11, wherein the death receptor agonist is an antibody against a death receptor, a derivative, or fragment thereof, selected from the group consisting of anti-CD95 antibody, anti-TRAIL-R1 antibody, anti-TRAIL-R2 antibody, anti-DR6 antibody, anti-TNF-R1 antibody, and anti-TRAMP antibody.

14. The method according to claim 1, wherein the active compound is a negative regulator of an anti-apoptotic protein.

15. The method according to claim 1, wherein the non-lymphoid or non-myeloid tumor is selected from the group consisting of bladder carcinoma, neuroblastoma, intestine carcinoma, rectum carcinoma, colon carcinoma, familiary adenomatous polyposis carcinoma, hereditary non-polyposis colorectal cancer, esophageal carcinoma, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric carcinoma, adenocarcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, follicular thyroid carcinoma, anaplastic thyroid carcinoma, renal carcinoma, kidney parenchym carcinoma, ovarian carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, pancreatic carcinoma, prostate carcinoma, testis carcinoma, breast carcinoma, urinary carcinoma, melanoma, brain tumor, glioblastoma, astrocytoma, meningioma, medulloblastoma, peripheral neuroectodermal tumor hepatocellular carcinoma, gall bladder carcinoma, bronchial carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, basalioma, teratoma, retinoblastoma, choroids melanoma, seminoma, rhabdornyosarcoma, craniopharyngeoma, osteosarcoma, chondrosarcoma, myosarcome, liposarcoma, fibrosarcoma, Ewing sarcoma, and plasmocytoma.

16. A method for the down-regulation of an anti-apoptotic protein in a non-lymphoid or non-myeloid tumor, the method comprising the steps of: (a) selecting a subject having a non-lymphoid or non-myeloid tumor producing a higher level of a cytokine as compared with normal tissue, wherein the cytokine is selected from the group consisting of interleukin (IL)-4, IL-5, IL-10, IL-13, and combinations thereof and having a higher level of an anti-apoptotic protein than a comparable control sample; and (b) contacting the non-lymphoid or non-myeloid tumor with a cytokine antagonist selected from the group consisting of a transcriptional regulator of the cytokine/cytokine receptor gene, an antisense nucleic acid molecule that is complementary to a region of the cytokine/cytokine receptor gene, a dsRNA molecule that is complementary to the cytokine/cytokine receptor mRNA, a ribozyme that cleaves the cytokine/cytokine receptor mRNA, a translational regulator of the cytokine/cytokine receptor mRNA, an aptamer which binds to the cytokine and/or cytokine receptor and prevents or disrupts the interaction between the cytokine and its receptor, an antibody or fragment thereof that binds to the cytokine/cytokine receptor, a receptor, a fragment or derivative thereof of the cytokine, CD124, CD132, IL-13R.alpha.-2, IL-10R.alpha., a cytokine trap, and a cytokine mutein wherein the anti-apoptotic protein in the non-lymphoid or non-myeloid tumor is down-regulated.

17. The method according to claim 16, wherein the cytokine antagonist is delivered to the proximity of or into the non-lymphoid or non-myeloid tumor.

18. The method according to claim 17, wherein the cytokine antagonist is delivered via a retroviral vector.

19. The method according to claim 1, wherein the non-lymphoid or non-myeloid tumor is a colon carcinoma.

20. The method according to claim 1, further comprising the steps of: (d) detecting the cytokine in a sample obtained from the subject.

21. The method according to claim 20, wherein step (d) comprises detecting a cytokine polypeptide.

22. The method according to claim 20, wherein step (d) comprises detecting a cytokine nucleic acid.

23. The method according to claim 4, wherein the antibody or fragment thereof that binds to the cytokine/cytokine receptor is an anti-IL-4 antibody or an anti-IL-4 receptor antibody or a fragment thereof.

24. The method according to claim 23, wherein the antibody or fragment thereof is an anti-IL-4 receptor antibody or a fragment thereof.

25. The method according to claim 5, wherein the antibody or fragment thereof is a bispecific antibody or fragment thereof.

26. The method according to claim 25, wherein the antibody or fragment thereof is a bispecific antibody or a fragment thereof binding to IL-4 and IL-10.

27. The method according to claim 16, wherein the cytokine antagonist is an antibody or fragment thereof that binds to the cytokine/cytokine receptor.

28. The method according to claim 27, wherein the antibody or fragment that binds to the cytokine/cytokine receptor is an antibody or fragment thereof that binds to IL-4, IL-10, or IL-13, and combinations thereof.

29. The method according to claim 27, wherein the antibody or fragment thereof that binds to the cytokine/cytokine receptor is an anti-IL-4 antibody or an anti-IL-4 receptor antibody or a fragment thereof.

30. The method according to claim 29, wherein the antibody or fragment thereof is an anti-IL-4 receptor antibody or a fragment thereof.

31. The method according to claim 29, wherein the antibody or fragment thereof is a bispecific antibody or fragment thereof.

32. The method according to claim 31, wherein the antibody or fragment thereof is a bispecific antibody or a fragment thereof binding to IL-4 and IL-10.

33. The method according to claim 1, wherein cells of the non-lymphoid or non-myeloid tumor are refractory to administration of the active compound or radiotherapy without administering of the cytokine antagonist.

34. The method according to claim 1, wherein an area of the non-lymphoid or non-myeloid tumor has been surgically removed from the subject.

35. The method according to claim 1, wherein cells of the non-lymphoid or non-myeloid tumor are resistant to an anti-cancer drug or resistant to apoptosis.

36. The method according to claim 1, wherein cells of the non-lymphoid or non-myeloid tumor show a multi-drug resistant phenotype.

37. The method according to claim 1, wherein the cytokine is IL-4.

38. The method according to claim 1, wherein the cytokine is IL-10.

39. The method according to claim 1, wherein the cytokine is IL-13.

40. The method according to claim 2, wherein the anti-apoptotic protein is Bcl-2.

41. The method according to claim 2, wherein the anti-apoptotic protein is Bcl-x.sub.L.

42. The method according to claim 2, wherein the anti-apoptotic protein is cFLIP.

43. The method according to claim 3, wherein the cytokine antagonist is a cytokine mutein.

44. The method according to claim 3, wherein the cytokine antagonist is a receptor, a fragment or derivative thereof of the cytokine.

45. The method according to claim 3, wherein the cytokine antagonist is an aptamer which binds to the cytokine and/or cytokine receptor and prevents or disrupts the interaction between the cytokine and its receptor.

46. The method according to claim 8, wherein the active compound is an intercalating agent.

47. The method according to claim 8, wherein the active compound is a microtubule-directed agent.

48. The method according to claim 8, wherein the active compound is a DNA cross-linking agent.

49. The method according to claim 8, wherein the active compound is an antineoplastic agent.

50. The method according to claim 9, wherein the active compound is cisplatin or cisplatinum.

51. The method according to claim 9, wherein the active compound is paclitaxel.

52. The method according to claim 9, wherein the active compound is daunorubicine.

53. The method according to claim 9, wherein the active compound is adriamycin.

54. The method according to claim 14, wherein the anti-apoptotic protein is an IAP.

55. The method according to claim 15, wherein the non-lymphoid or non-myeloid tumor is prostate carcinoma.

56. The method according to claim 15, wherein the non-lymphoid or non-myeloid tumor is breast carcinoma.

57. The method according to claim 15, wherein the non-lymphoid or non-myeloid tumor is medullary thyroid carcinoma, papillary thyroid carcinoma, follicular thyroid carcinoma or anaplastic thyroid carcinoma.

58. The method according to claim 15, wherein the non-lymphoid or non-myeloid minor is colon carcinoma, familiary adenomatous polyposis carcinoma or hereditary non-polyposis colorectal cancer.

59. The method according to claim 15, wherein the non-lymphoid or non-lymphoid tumor is bladder carcinoma.

60. The method according to claim 15, wherein the non-lymphoid or non-myeloid tumor is urinary carcinoma.

61. The method according to claim 15, wherein the non-lymphoid or non-myeloid tumor is pancreatic carcinoma.

62. The method according to claim 16, wherein the cytokine antagonist is a cytokine mutein.

63. The method according to claim 16, wherein the cytokine antagonist is a receptor, a fragment or derivative thereof of the cytokine.

64. The method according to claim 16, wherein the cytokine antagonist is an aptamer which binds to the cytokine and/or cytokine receptor and prevents or disrupts the interaction between the cytokine and its receptor.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
03002603Feb 07, 2003
PCT Information
PCT FiledFebruary 09, 2004PCT Application Number:PCT/EP2004/001177
PCT Publication Date:August 19, 2004PCT Publication Number:WO2004/069274

Details for Patent 7,645,449

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10   Start Trial 2023-02-07 RX search
Sigma Tau ONCASPAR pegaspargase VIAL 103411 001 1994-02-01   Start Trial 2023-02-07 RX search
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Start Trial 2023-02-07 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Colorcon
Mallinckrodt
Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.